GCCL Receives Frost & Sullivan 'Asia-Pacific Customer Value Leadership Award'

GCCL, a clinical trial specimen analysis organization, received the '2025 Best Practice Customer Value Leadership Award' in the Asia-Pacific (APAC) clinical trial specimen analysis service industry from the global market research firm Frost & Sullivan. Photo by GCCL

Clinical trial specimen analysis organization GCCL announced on the 6th that it has received the '2025 Best Practice Customer Value Leadership Award' in the Asia-Pacific (APAC) clinical trial specimen analysis service sector from the global market research firm Frost & Sullivan.

Frost & Sullivan is a globally prestigious organization that selects and awards innovative companies and products that have achieved outstanding performance in the global market. In particular, the Customer Value Leadership Award is only given to companies that provide exceptional value to their customers. This category is judged and selected based on five rigorous criteria: growth rate, innovation, customer satisfaction, market dominance, and social responsibility. GCCL met all these criteria and was honored with the award in recognition of its customer-centric management philosophy and outstanding technological capabilities.

GCCL operates a 'one-stop lab solution' that integrates a Central Lab, Bioanalysis Lab, and BL3 facility in the global market. Through this, it minimizes sample movement, significantly reducing time and costs while ensuring sample stability to provide more reliable data. In addition, by adopting state-of-the-art analytical platforms and a global Laboratory Information Management System (LIMS), GCCL not only meets high-quality standards in the clinical research field but also offers customized analytical solutions for each client, establishing itself as a trusted partner in new drug development.

Frost & Sullivan highly evaluated GCCL’s comprehensive lab service delivery model through multiple rigorous assessments, citing its systematic quality control and technological innovation leading the industry as the main reasons for this award. Through this, GCCL has once again proven its competitiveness by providing consistent and reliable solutions to customers as a leading company in the clinical trial specimen analysis service sector in the APAC region.

Jo Gwan-gu, CEO of GCCL, said, "This award is a globally recognized achievement of GCCL’s efforts and capabilities that prioritize realizing customer value, and it proves that GCCL has firmly established itself as a market-leading company. We will continue to grow as a trusted partner of global new drug developers by keeping pace with the increasing global demand for clinical trials through continuous technological innovation and service quality enhancement."

GCCL is a clinical trial specimen analysis organization that has obtained full certification in all areas of the Ministry of Food and Drug Safety’s GCLP (Good Clinical Laboratory Practice) and provides customized clinical analysis services that meet global standards for the entire clinical trial cycle from Phase 1 to Phase 4. Based on various analytical platforms aligned with global quality standards, including the introduction of ddPCR equipment, and specialized specimen analysis and method development services, GCCL supports clinical trial specimen analysis not only for domestic pharmaceutical and bio companies but also for partners across the Asia region and worldwide.

This content was produced with the assistance of AI translation services.